Meeting BioPharma Needs For Lower Operating Cost And Faster Time To MarketSource: PBS Biotech, Inc.
Broad adoption awaits fully scalable GMP systems, improved and less costly disposables, better analytics, greater process automation and low-shear mixing.
Today, more cell cultures for both mainstream and pipeline drugs and vaccines are rocked, stirred, mixed, perfused and harvested using single-use systems. PBS Biotech® is leading the technology and value-creation charge of these new systems, which are taking market share from traditional glass and stainless steel bioreactors.
Competition is now heated across continents for accelerating new pharmaceutical products (including biosimilars) to market. The single-use bioreactor system is an ideal solution to create rapid capacity gains, enable fast changeover, boost process efficiency and drive costs out of operations. Innovative, modular and easier platforms and technology are emerging that offer better performance for biopharmaceuticals and an economical approach to meeting production needs.